BAF

Foghorn Therapeutics Provides Third Quarter 2023 Financial and Corporate Update

Retrieved on: 
星期四, 十一月 2, 2023
Research, NSCLC, EP300, IND, Thrombocytopenia, MDS, Preclinical development, Colorectal cancer, Merck, Chromatin, Factorization of polynomials, Prostate cancer, Hanson, LDAC, ARID1B, Clinical trial, CBP, BRG1, BRM, Safety, Investment, AR, Patient, Gene expression, BAF, Prostate, Mutation, State Administrative Expenses, Cancer, Pharmaceutical industry, Vaccine, Decitabine, Foghorn, AML

“During the third quarter, we continued to enroll patients in our FHD-286 combination study in AML and expect to have data in the second half of 2024.

Key Points: 
  • “During the third quarter, we continued to enroll patients in our FHD-286 combination study in AML and expect to have data in the second half of 2024.
  • Foghorn commenced a Phase 1 study of FHD-286 in combination with decitabine or low-dose cytarabine (LDAC) in relapsed and/or refractory AML patients, with the first patient dosed during the third quarter of 2023.
  • As of September 30, 2023, the Company had $259.9 million in cash, cash equivalents and marketable securities, which provides cash runway into the first half of 2026.
  • Net loss was $14.3 million for the three months ended September 30, 2023, compared to a net loss of $25.8 million for the three months ended September 30, 2022.

Foghorn Therapeutics to Present Clinical and Pre-Clinical Data from Multiple Programs Across Its Diverse Pipeline at AACR-NCI-EORTC International Conference

Retrieved on: 
星期三, 十月 4, 2023
Synovial sarcoma, AACR, UM, CBP, DLBCL, Foghorn, NGS, Chromatin, BRM, BRG1, Mum, Gene expression, NSCLC, Prostate, Biomarker, Lung cancer, EP300, Acute myeloid leukemia, B cell, MDS, Malignancy, AML, BAF, Patient, Lymphoma, Neoplasm, BRD9, AR, Conference, Prostate cancer, Pharmaceutical industry, Vaccine, Science

The conference will be held October 11–15, 2023, in Boston, Massachusetts.

Key Points: 
  • The conference will be held October 11–15, 2023, in Boston, Massachusetts.
  • Foghorn will highlight data from its FHD-286 program demonstrating its potential as a broad-based hematologic and solid tumor differentiation agent, including clinical data in acute myeloid leukemia (AML), metastatic uveal melanoma (mUM), and pre-clinical data in non-small cell lung cancer (NSCLC) and prostate cancer.
  • Also at AACR-NCI-EORTC, the Company will present data from its selective EP300 program, including in vitro selective degradation and antiproliferation in AR+ prostate and DLBCL cell lines.
  • The EP300 program targets CBP mutant cancers and subsets of EP300 dependent malignancies, which include bladder, NSCLC, and various leukemias and lymphomas.

Brain Aneurysm Foundation Announces 2023 Research Grants

Retrieved on: 
星期四, 九月 21, 2023
Subarachnoid hemorrhage, Bleeding, Therapy, Beth Israel Deaconess Medical Center, Education, Genetics, Prevalence, Blood, Epigenetics, Impact, Aneurysm, Stroke, Policy, Kick, Aortic rupture, Skull, Research, Risk, Brain, Biomarker, Pop, Science, SAH, ZIC3, BAF, Rupture, Robotics, HDAC2, Big data, Biology, Effectiveness, Diagnosis, Ecosystem, Role, Comparative effectiveness research, Health, Headache, Woman, Social media, Disease, Pharmaceutical industry, Mouse, Engagement

HANOVER, Mass., Sept. 21, 2023 /PRNewswire/ -- The Brain Aneurysm Foundation (BAF), the leading advocacy organization supporting education, research, and policy to transform the treatment of brain aneurysms, today announced the recipients of its 2023 research grants, providing support to academic researchers studying the underlying biology of aneurysms or developing new treatment methods.

Key Points: 
  • Provides Funding for 17 Research Efforts that aim to Address the Underlying Causes of Disease, New Treatment Paradigms and Key Markers of Ruptures and Hemorrhage
    Total Annual Research Funding Eclipses $5 million; BAF Kicks off its Annual Day of Engagement to Support its Mission of Reducing the Prevalence and Impact of Brain Aneurysms
    HANOVER, Mass., Sept. 21, 2023 /PRNewswire/ -- The Brain Aneurysm Foundation (BAF), the leading advocacy organization supporting education, research, and policy to transform the treatment of brain aneurysms, today announced the recipients of its 2023 research grants, providing support to academic researchers studying the underlying biology of aneurysms or developing new treatment methods.
  • Research grants are a cornerstone of the organization's mission, as it works to fund critical advances at a time where Federal dollars for brain aneurysm research amounts to just over $2 for every person afflicted.
  • A brain aneurysm is a weak, bulging area in an artery in the brain that in some instances can rupture.
  • Women over the age of 55 have a higher risk of brain aneurysm rupture than men and are generally at greater risk.

African Diaspora Network Invites Investors to Sixth Annual Builders of Africa's Future Pitch Session

Retrieved on: 
星期二, 九月 12, 2023
Conrad N. Hilton Foundation, Heart, Learning, Fintech, Partnership, Education, McGovern-Dole International Food for Education and Child Nutrition Program, ADN, Eastern and Southern African Management Institute, Conrad, Recycling, Associate, United States African Development Foundation, Organization, Entrepreneurship, African diaspora, BAF, USADF, Child, AMI, Builder, Coffee, Cryptocurrency, Nursing, African, Future

SILICON VALLEY, Calif., Sept. 12, 2023 /PRNewswire-PRWeb/ -- On Tuesday, September 12, the African Diaspora Network will host its sixth annual virtual pitch session for ten grassroots African entrepreneurs participating in the 2023 Builders of Africa's Future (BAF) program. The virtual session provides a platform for the Builders to showcase their startups to investors and industry leaders interested in funding and supporting their ventures. Builders of Africa's Future is an enterprise accelerator organized by the African Diaspora Network (ADN) in partnership with Conrad N. Hilton Foundation and the United States African Development Foundation (USADF), with enterprise training provided by the African Management Institute (AMI). 

Key Points: 
  • SILICON VALLEY, Calif., Sept. 12, 2023 /PRNewswire-PRWeb/ -- On Tuesday, September 12, the African Diaspora Network will host its sixth annual virtual pitch session for ten grassroots African entrepreneurs participating in the 2023 Builders of Africa's Future (BAF) program.
  • Builders of Africa's Future is an enterprise accelerator organized by the African Diaspora Network (ADN) in partnership with Conrad N. Hilton Foundation and the United States African Development Foundation (USADF), with enterprise training provided by the African Management Institute (AMI).
  • African Diaspora Network invites private and public investors looking to invest in impactful, grassroots startups in Africa to attend.
  • Interested investors can register to attend the Builders of Africa's Future Pitch Day here or email [email protected] for more information.

With One-in-Fifty People in the US at Risk, the Brain Aneurysm Foundation Launches New Campaign to Increase Disease Awareness and Accelerate Research

Retrieved on: 
星期三, 九月 6, 2023
Survivor, Fibromuscular dysplasia, Marfan syndrome, Beth Israel Deaconess Medical Center, Education, Prevalence, Blood, Stroke, Policy, Aortic rupture, Skull, Research, Brain, Risk, Pop, Pain, Subarachnoid hemorrhage, Polycystic kidney disease, BAF, Rupture, Patient, Physician, Need, Seizure, Nerve, Nausea, Biology, Diagnosis, City, Headache, Woman, Smoking, Death, Family, Memory, Social media, Autosome, Disease, Ehlers–Danlos syndromes, Pharmaceutical industry, Nursing, Aneurysm

HANOVER, Mass., Sept. 6, 2023 /PRNewswire/ -- The Brain Aneurysm Foundation (BAF), the leading advocacy organization supporting education, research, and policy to transform the treatment of brain aneurysms, today announced the launch of "Stop the Pop," a new campaign to increase awareness of the prevalence and impact of the disease and the need for ongoing investment to fund new innovations, screening, and treatment. 

Key Points: 
  • The campaign aims to build awareness of symptoms, genetic and environmental risk factors, and to increase research funding to better understand the underlying causes of the condition and to advance new treatments.
  • "A feeling that something has 'popped' is what we hear most from patients who have experienced a rupture.
  • A brain aneurysm is a weak, bulging area in an artery in the brain that in some instances can rupture.
  • Women over the age of 55 have a higher risk of brain aneurysm rupture than men and are generally at greater risk.

Foghorn Therapeutics Provides Second Quarter 2023 Financial and Corporate Update

Retrieved on: 
星期五, 八月 4, 2023
ARID1B, Therapy, CBP, Selective, CDX, Chromatin, Clinical trial, BRM, Uveal melanoma, BRG1, Mum, Gene expression, NSCLC, EP300, Preclinical development, PDX, Science, MDS, State Administrative Expenses, AML, Merck & Co., BAF, Lilly, Patient, Investment, LDAC, Biology, Research, IND, Factorization of polynomials, Safety, Prostate cancer, Pharmaceutical industry, Vaccine, Decitabine, Foghorn

CAMBRIDGE, Mass., Aug. 04, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today provided a financial and corporate update in conjunction with the Company’s 10-Q filing for the quarter ended June 30, 2023. With an initial focus in oncology, Foghorn’s Gene Traffic Control® Platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.

Key Points: 
  • “Foghorn made important progress across both our clinical and preclinical pipeline in the second quarter.
  • We are on track to initiate dosing in a combination study of FHD-286 in AML in the third quarter.
  • On June 28, 2023, Foghorn announced data from the Phase 1 dose escalation safety study of FHD-286 in metastatic uveal melanoma (mUM).
  • As of June 30, 2023, the Company had $284.3 million in cash, cash equivalents and marketable securities, which provides a cash runway into the second half of 2025.

EQS-News: Nordex SE: ​​​​​​​Nordex Group supplies 12 turbines for the Erftstadt-Friesheim wind farm in Germany

Retrieved on: 
星期四, 七月 6, 2023
Workforce, Maintenance, Air navigation service provider, Atmosphere, Deutsche Flugsicherung, Wind, EUR, BAF, Radio, REA, Renewable energy

The German developer REA has placed an order with the Nordex Group for the supply of 12 turbines with a total capacity of 43 MW.

Key Points: 
  • The German developer REA has placed an order with the Nordex Group for the supply of 12 turbines with a total capacity of 43 MW.
  • Eight turbines of the type N117/3600, and four turbines of the type N131/3600, with a rated output of 3.6 MW each, will be installed.
  • The order also includes a Premium Service contract for the maintenance and servicing of the turbines for a period of 20 years.
  • The change is intended to create further potential for areas for wind energy production in Germany.

African Diaspora Network Elevates Ten Early Stage African Entrepreneurs with the Sixth Annual Builders of Africa's Future Award

Retrieved on: 
星期二, 六月 13, 2023
Diaspora, AIT, ADN, United States African Development Foundation, Fintech, Innovation, Conrad, Sustainable energy, Organization, Silicon, BAF, Eastern and Southern African Management Institute, USADF, Poultry farming, Builder, Growth, Education, Conrad N. Hilton Foundation, Management, Recycling

SILICON VALLEY, Calif., June 13, 2023 /PRNewswire-PRWeb/ -- African Diaspora Network (ADN), for the sixth consecutive year, is supporting the rising stars of African entrepreneurship with the Builders of Africa's Future (BAF) award which celebrates innovation and impact in early-stage African enterprises. The sixth cohort of the BAF launched today with 10 entrepreneurs from Cameroon, Ghana, Kenya, Nigeria, and Uganda. All participating organizations in the cohort are 100% African-led and owned, operating in the Education, Recycling, Health Tech & Innovation, Poultry Farming, FinTech, Green Energy, and Coffee Farming sectors.

Key Points: 
  • African Diaspora Network launches the sixth cohort of the Builders of Africa's Future award in support of innovation and impact in early stage African enterprises.
  • SILICON VALLEY, Calif., June 13, 2023 /PRNewswire-PRWeb/ -- African Diaspora Network (ADN), for the sixth consecutive year, is supporting the rising stars of African entrepreneurship with the Builders of Africa's Future (BAF) award which celebrates innovation and impact in early-stage African enterprises.
  • The sixth cohort of the BAF launched today with 10 entrepreneurs from Cameroon, Ghana, Kenya, Nigeria, and Uganda.
  • African Diaspora Network through BAF, will help scale their ventures and impact in their respective sectors.

Foghorn Therapeutics Provides First Quarter 2023 Financial and Corporate Update

Retrieved on: 
星期一, 五月 8, 2023
Synovial sarcoma, ARID1B, Therapy, CBP, Selective, Chromatin, BRM, Uveal melanoma, BRG1, Mum, Gene expression, NSCLC, Lung cancer, EP300, Science, MDS, State Administrative Expenses, AML, Merck & Co., BAF, Lilly, Patient, Investment, Data, Biology, Research, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, IND, Conference, Factorization of polynomials, Food, Prostate cancer, Pharmaceutical industry, Cryptocurrency, Foghorn

Top-line Phase 1 safety and efficacy data is expected in the second quarter of 2023.

Key Points: 
  • Top-line Phase 1 safety and efficacy data is expected in the second quarter of 2023.
  • The Company anticipates providing a regulatory update for FHD-286 in AML/MDS in the second quarter of 2023.
  • On April 24, 2023, Foghorn provided an update on the FHD-609 Phase 1 program in synovial sarcoma and SMARCB1-deleted tumors.
  • In 2023, Foghorn will continue to utilize its Gene Traffic Control platform to discover and develop novel therapeutics under the collaboration based on disruptors of a specified transcription factor target.

Foghorn Therapeutics to Present Preclinical Data from Its Selective CBP and EP300 Protein Degrader Programs and Preclinical Data for FHD-286, a Potent, Selective Inhibitor of BRG1 and BRM, at the 2023 American Association for Cancer Research Annual Meetin

Retrieved on: 
星期一, 四月 10, 2023
AACR, Selective, CBP, Foghorn, Chromatin, Skin, BRM, Uveal melanoma, Breast, BRG1, Gene expression, NSCLC, Prostate, Lung cancer, EP300, Lung, MDS, Malignancy, AML, Discovery, BAF, Lymphoma, Leukemia, Therapy, MD Anderson Cancer Center, Biology, Pharmaceutical industry, Glass fiber, Management, Science

Also at AACR, the company will provide an overview of its Selective EP300 and Selective CBP degrader programs.

Key Points: 
  • Also at AACR, the company will provide an overview of its Selective EP300 and Selective CBP degrader programs.
  • The EP300 program targets CBP mutant cancers and subsets of EP300 dependent malignancies, which include bladder, NSCLC, and various leukemias and lymphomas.
  • The CBP program is focused on a wide number of EP300 mutant cancers, including prostate, bladder, colorectal, breast, gastric, and lung.
  • If successful, the Selective EP300 and Selective CBP programs have the potential to address significant unmet medical need in large patient populations.